A Cancer Research UK Phase I dose escalation trial of oral VEGFR and EGFR inhibitor, Vandetanib in combination with the oral MEK inhibitor, Selumetinib (VanSel-1) in solid tumours (dose escalation) and NSCLC (expansion cohort)
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2016
At a glance
- Drugs Selumetinib (Primary) ; Vandetanib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Acronyms VanSel1
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 09 May 2016 Planned number of patients changed from 75 to 80.
- 04 Nov 2015 Accrual to date is 65% according to United Kingdom Clinical Research Network.